Please enable Javascript
Localized Renal Cell Carcinoma
Advertisement
Partial Nephrectomy as an Alternative to Radical Nephrectomy for Patients With pT3aN0M0 RCC
Katy Marshall
SUO 2023
|
November 30, 2023
Investigators used multivariable analysis and Kaplan-Meier analysis to compare partial nephrectomy with radical nephrectomy.
Read More
Kidney Cancer: Acting on Disparities and Intervening for Small Renal Masses
Zachary Bessette
SUO 2023
|
November 30, 2023
Drs. Woldu and Pierorazio presented on disparities in RCC care and outcomes as well as appropriate AS in small renal masses.
Read More
Partial, Radical Nephrectomy After ICIs for Complex Locally Advanced RCC
Zachary Bessette
SUO 2023
|
November 22, 2023
Surgery for locally advanced RCC may be safe for patients after neoadjuvant durvalumab with or without tremelimumab.
Read More
Analyzing the Prognostic Potential of Biomarkers for ccRCC Treatment Stratification
Emily Menendez
2023 IKCS: North America
|
November 13, 2023
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Read More
Under-Utilization, Disparities in Genetic Testing for Patients With RCC
Katy Marshall
2023 IKCS: North America
|
November 10, 2023
Patients with early-onset RCC underwent genetic testing more often than those with bilateral RCC.
Read More
Impact of Diabetes on Survival in Patients Undergoing Nephrectomy
Zachary Bessette
2023 IKCS: North America
|
November 10, 2023
A Danish study suggests that diabetes has a significant impact on OS in patients with RCC who undergo nephrectomy.
Read More
International Germline Susceptibility to RCC, Implications for Genetic Screening
Zachary Bessette
2023 IKCS: North America
|
November 10, 2023
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
Read More
KEYNOTE-564: New Results Show OS Benefit of Pembrolizumab as Adjuvant RCC Therapy
Emily Menendez
Localized Renal Cell Carcinoma
|
November 8, 2023
The anti-PD-1 therapy met the trial’s key secondary endpoint of OS for patients with RCC following nephrectomy.
Read More
Diabetes, Older Age, Higher BMI Found to Influence Pathological Upstaging in Patients With Nonmetastatic RCC
Emily Menendez
Localized Renal Cell Carcinoma
|
November 3, 2023
Certain risk factors can result in pathological upstaging in patients treated with nephrectomy for nonmetastatic RCC.
Read More
IROCK Report: 5-Year Renal Function Outcomes After SABR for Primary RCC
Zachary Bessette
ASTRO 2023
|
October 3, 2023
New data compares renal function outcomes of SABR in patients with solitary versus bilateral kidneys.
Read More
FASTRACK II: High-Dose Radiation Effective in Older Patients With Inoperable Kidney Tumors
Zachary Bessette
ASTRO 2023
|
October 2, 2023
Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted, high-dose radiation.
Read More
Hans Hammers, MD, PhD – Driving Immunotherapy Combinations Into the Modern Age of Kidney Cancer Care
Hans Hammers, MD, PhD
Renal Cell Carcinoma
|
September 8, 2023
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
Read More
Novel Single-Port Approaches to Traditional Multiport Surgeries
Akhil Abraham Saji, MD
Localized
|
November 29, 2023
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
Read More
Predictive Model Identifies Patients Most at Risk for Kidney Failure After Nephrectomy
Emily Menendez
Localized Renal Cell Carcinoma
|
August 29, 2023
While nephrectomy is a common treatment for kidney cancer, it can result in loss of kidney function or kidney failure.
Read More
Does Everolimus Improve Recurrence Risk for RCC With Surgical Resection?
Emily Menendez
Localized Renal Cell Carcinoma
|
August 18, 2023
The EVEREST trial analyzed the effectiveness of everolimus in patients with RCC who have undergone full surgical resection.
Read More
Dr. Jérémie Calais on a Novel Radiotracer That Detects, Differentiates Renal Cell Carcinomas
Jérémie Calais, MD, MSc
SNMMI 2023
|
July 28, 2023
Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.
View More
Surgical Management of Kidney Cancer Impactful but Associated With Unanswered Questions
Leah Lawrence
Localized Renal Cell Carcinoma
|
July 7, 2023
Several experts discuss the evolution of nephrectomy, how it is used today, which patients are best suited for it, and more.
Read More
New Machine Learning Methodology Helps Identify Cancerous Kidney Tissue
Emily Menendez
Localized Renal Cell Carcinoma
|
June 26, 2023
To identify positive surgical margins, researchers used DESI-MSI to to distinguish normal tissue from RCC tissue samples.
Read More
Adjuvant Nivolumab Plus Ipilimumab in Localized RCC: Subgroup Analyses of CheckMate 914
Zachary Bessette
ASCO 2023
|
May 30, 2023
Tumor grade, sarcomatoid features may influence outcomes with adjuvant nivo/ipi in patients with RCC after nephrectomy.
Read More
Evaluating the Safety of Retroperitoneal Laparoscopic Partial Nephrectomy for Localized RCC
Emily Menendez
Localized Renal Cell Carcinoma
|
May 11, 2023
Partial nephrectomy has been gaining traction as an effective treatment for RCC due to its safety and efficacy.
Read More
Load More
Advertisement
Advertisement
Advertisement